Thank you for the feedback, so with that government potential reimbursement in the long run,
plus the accredited laboratories for diagnostic and the possible creation of a large and diverse portfolio of future tests,
the company is potentially in two years( let's assume) is adding a new avenue of revenue. that will be a major transformation, as currently, the expense to EBITDA is around 2-3 million a year, may change to a
2-3 million profit in EBITDA in (lets assume) two years, thats a turn around of 5 mil in EBITDA.
Looks great in theory, I am prepared to hold this little company even longer if the potential n story keeps on rolling.
ITD Price at posting:
52.0¢ Sentiment: Buy Disclosure: Held